Relmada FY2025 net loss $57.4M; NDV-01 76% CR at 12 months; $160M PIPE closed

RELMADA THERAPEUTICS, INC.

FY2025 net loss $57.4M ($1.45/share) vs $80.0M in FY2024; Q4 net loss $19.9M ($0.27/share).
NDV-01 Phase 2: 95% CR at any time, 76% durable CR at 12 months in high-risk NMIBC; BCG-unresponsive 80% CR at 12 months.
Oversubscribed $160M PIPE closed March 2026; cash $93M at Dec 31, 2025 plus PIPE expected to fund operations through 2029.
R&D expense $26.9M (down from $46.2M); G&A $32.2M (down from $37.7M); shares outstanding 104.9M.
On track to start Phase 3 RESCUE program and Sepranolone Phase 2 in Prader-Willi mid-2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-032403

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.